Description

Abbott Laboratories’ CGM Growth Story Looks Obvious—But the NEXT Leg Is Even Bigger!

Abbott Laboratories’ fourth quarter of 2025 earnings call offers a comprehensive view of the company’s current financial standings and future outlook. The call highlighted Abbott’s adherence to innovation, effective execution of strategies, and strategic acquisitions intended to bolster long-term growth prospects. In the fourth quarter, Abbott reported a sales increase of 3.8% when excluding COVID-19 testing sales, and achieved an adjusted earnings per share of $1.50, marking a 12% growth compared to the previous year. This performance illustrates Abbott’s ability to adapt to market conditions and maintain growth, although challenges persist in certain segments, notably the Nutrition division, where sales have declined. Pressure from increasing manufacturing costs and subsequent price hikes have constrained volume growth. Abbott is revising its strategy with pricing and promotional initiatives aiming to reinvigorate demand and prepare for a potential return to growth in the second half of 2026.